ANTI-INFLAMMATORY THERAPY FOR ATHEROSCLEROSIS: CONTRIBUTION TO AND LESSONS OF RHEUMATOLOGY

According to modern views, chronic low-grade inflammation, the development of which is associated with the uncontrolled activation of both innate and acquired immunity, plays a fundamental role at all stages of the atherosclerotic process. The contribution of inflammation to the development of an atherosclerotic vascular lesion drew attention to the similarity of the mechanisms in the immunopathogenesis of atherosclerosis and the classic immunoinflammatory disease (IID) – rheumatoid arthritis (RA). Interleukin 1β (IL-1β), which plays an important role in the development of many acute and chronic IIDs, is of particular interest with regard to its implication in the pathogenesis of an atherosclerotic vascular lesion and as a promising therapeutic target. The atherosclerosis development mechanisms related to IL-1β determine the ability of cholesterol crystals and other proatherogenic factors to induce IL-1β synthesis due to NLRP3 inflammasome activation. There is strong evidence that inflammation plays a role in the development of atherosclerosis as a whole and that anti-inflammatory therapy has good prospects particularly in the randomized placebo-controlled trial (RPCT) CANTOS (Canakinumab ANti-inflammatory Thrombosis Outcomes Study) investigating the efficiency of treatment with canakinumab (Novartis International AG), an anti-IL-1β monoclonal antibodies, in patients with severe atherosclerotic vascular lesions as a new approach to secondary prevention of cardiovascular events. Methotrexate (MTX) has now been convincingly shown to be an effective drug (a gold standard) in not only controlling the inflammatory activity of RA, but also in significantly reducing the risks of cardiovascular catastrophes. This has served as a basis for planning the RPCT CIRT (The Cardiovascular Inflammation Reduction Trial) to evaluate the antiatherogenic effect of MTX in the general population of patients with coronary heart disease. The CANTOS results and the experience gained in rheumatology to determine the cardiovascular effects of innovative anti-inflammatory drugs are of great importance in improving the secondary prevention of atherosclerosis-related cardiovascular events.

1. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340:115-26. doi: 10.1056/NEJM199901143400207

2. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38. doi: 10.1016/j.jacc.2009.09.009

3. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-56. doi: 10.1161/CIRCRESAHA.115.306656

4. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124-6. doi: 10.1161/01.CIR.100.21.2124

5. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how «high-grade» systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108(24):2957-63. doi: 10.1161/01.CIR.0000099844.31524.05

6. Насонов ЕЛ. Проблема атеротромбоза в ревматологии. Вестник РАМН. 2003;(7):6-10 [Nasonov EL. The problem of atherothrombosis in rheumatology. Vestnik RAMN. 2003;(7):6- 10 (In Russ.)].

7. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015 Jul;11(7):390-400. doi: 10.1038/nrrheum.2015.40

8. Насонов ЕЛ, Попкова ТВ, Новикова ДС. Сердечно-сосудистая патология при ревматических заболеваниях. Терапевтический архив. 2016;(5):3-10 [Nasonov EL, Popkova TV, Novikova DS. Cardiovascular pathology in rheumatic diseases. Terapevticheskii Arkhiv. 2016;(5):3-10 (In Russ.)].

9. Nurmohamed NT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11:693-704. doi: 10.1038/nrrheum.2015.112

10. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА- ПРЕСС; 2013 [Nasonov EL, editor. Genno- inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA- PRESS; 2013].

11. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409- 19 (In Russ.)]. doi: 10.14412/1995-4484-2017-409-419

12. Kenneth FB, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2017-211555

13. Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. doi: 10.1136/ard.2009.123919

14. Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheum. 2015;67(6):1449-55. doi: 10.1002/art.39098

15. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Molecular Med. 2014;20 Suppl 1:S43-S58. doi: 10.2119/molmed.2014.00232

16. Kraakman MJ, Dragoljevic D, Kammoun HL, Murphy AJ. Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. Clin Transl Immunol. 2016;5(5):e84. doi: 10.1038/cti.2016.31

17. Tousoulis D, Oikonomou E, Economou EK, et al. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016;37:1723-32. doi: 10.1093/eurheartj/ehv759

18. Reis A, Siegat NM, de Leon J. Interkeukin-6 in atherosclerosis: atherogenic or atheroprotective. Clin Lipidol. 2017;12:14023.

19. Robert M, Miossec P. Effects of interleukin 17 on the cardiovascular system. Autoimmun Rev. 2017;16:984-91. doi: 10.1016/j.autrev.2017.07.009

20. Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77

21. Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016;12(1):14-24. doi: 10.1038/nrrheum.2016.166

22. Karasawa T, Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb. 2017 May 1;24(5):443-51. doi: 10.5551/jat.RV17001

23. Gram H. Preclinical characterization and clinical development of ILARIS® (canakinumab) for the treatment of autoinflammatory diseases. Curr Opin Chem Biol. 2016;32:1-9. doi: 10.1016/j.cbpa.2015.12.003

24. Demin I, Hamren B, Luttringer O, et al. Longitudinal modelbased meta-analysis in rheumatoid arthritis: an application toward model-based drug development. Clinical Pharm Ther. 2012;92:352-9. doi: 10.1038/clpt.2012.69

25. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti- inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. doi: 10.1016/j.ahj.2011.06.012

26. Van Tassel BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013;128:1910-23. doi: 10.1161/CIRCULATION.113.003199

27. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126:2739-48. doi: 10.1161/CIRCULATIONAHA.112.122556

28. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Aug 27. doi: 10.1056/NEJMoa1707914

29. Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37:1720-2. doi: 10.1093/eurheartj/ehw024

30. Ridker PM, MacFadyen JG, Thuren T, et al; CANTOS Trial Group. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 25. doi: 10.1016/S0140-6736(17)32247-X

31. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99. doi: 10.1016/j.cell.2010.01.025

32. Herder C, Dalmas E, Boni-Schnetzler M, Donath MY. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metasb. 2015;26:551-63. doi: 0rg/10.1016/j.tem.2015.08.001

33. Rissanen A, Howard CP, Botha J, Thuren T; Global Investigators. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab. 2012;14:1088-96. doi: 10.1111/j.1463-1326.2012.01637.x

34. Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 2013;39:524-31. doi: 10.1016/j.diabet.2013.07.003

35. Stahel M, Becker M, Graf N, Michels S. Systemic interleukin 1β inhibition in proliferative diabetic retinopathy: A Prospective Open- Label Study Using Canakinumab. Retina. 2015 [Epub ahead of print].

36. Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421- 33 (In Russ.)]. doi: 10.14412/1995-4484-2015-421-433

37. Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL. Cardiovascular effects of methotrexate in rheumatoid arthritis. Curr Med Chem. 2015;22:1903-10. doi: 10.2174/0929867322666150415122039

38. Thornton CC, Al-Rashed F, Calay D, et al. Methptrexate-mediated activation of an AMPK- CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis. 2016;75:439-48. doi: 10.1136/annrheumdis-2014-206305

39. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Hemost. 2009;7 Suppl 1:332-9. doi: 10.1111/j1538-7836.2009.03404x

40. Everett B, Pradhan AD, Solomon DH, et al. Rationale and design of the cardiovascular inflammation reduction trial: a test of the anflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166;199-207. doi: 10.1016/j.ahj.2013.03.018

41. Erhayiem B, Pavitt S, Baxter P, et al. Coronary artery disease evaluation in rheumatoid arthritis (CADERA): study protocol for a randiomized controlled trial. Trials. 2014;15:436. doi: 10.1186/1745-6215-15-436

42. Leung YY, Hui LLY, Kraus VB. Colchicine – update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-50. doi: 10.1016/j.semarthrit.2015.06.013

43. Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease NLRP3- activated inflammation and improve obesityrelated metabolic dysregulation. Med Hypotheses. 2016;92:67-73. doi: 10.1016/j.mehy.2016.04.039

44. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-10. doi: 10.1016/j.jacc.2012.10.027

45. Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458-64. doi: 10.3899/jrheum.111533

46. Rock KL, Kataoka H, Lai J-J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13-23. doi: 10.1038/nrheum.2012/143

47. Елисеев МС, Желябина ОВ, Маркеловa ЕИ и др. Оценка кардиоваскулярного риска при применении ингибитора интерлейкина 1 у больных тяжелой тофусной подагрой. Современная ревматология. 2016;10(1):7-14 [Eliseev MS, Zhelyabina OV, Markelova EI, et al. Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2016;10(1):7-14 (In Russ.)]. doi: 10.14412/1996-7012-2016-1-7-14

48. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013;43(2):264-72. doi: 10.1016/j.semarthrit.2013.01.001

49. Sun L, Liu M, Li R, et al. Hydroxychloroquine, a promising choice for coronary artery disease? Med Hypotheses. 2016;93:5-7. doi: 10.1016/j.mehy.2016.04.045

50. Sharma TS, Wasko MC, Tang X, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 2016;4:5(1). doi: 10.1161/JAHA.115.002867

51. Restrepo JF, Del Rincon I, Molina E, et al. Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients. J Clin Rheumatol. 2017;23(3):144-8. doi: 10.1097/RHU.0000000000000502

52. Charles-Schoeman C, Yin Lee Y, Shahbazian A, et al. Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheum. 2017;69(1):46-57. doi: 10.1002/art.39833

53. Myasoedova E. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk. Curr Opin Rheumatol. 2017;29(3):277-84. doi: 10.1097/BOR.0000000000000378